Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) was featured in a newly published initiation report from Diamond Equity Research, highlighting the company's position as a commercial-stage psychedelic manufacturer with licensed GMP infrastructure and growing traction in Australia. The report, which was commissioned by Optimi, outlines the company's potential operating leverage as prescription demand for psychedelic-assisted therapies scales.
The Diamond report cites Optimi's regulatory licenses, existing MDMA and psilocybin manufacturing capacity, and expanding commercial activity in Australia, while also noting longer-term U.S. optionality. The report includes an illustrative valuation based on discounted cash flow analysis. Diamond noted that Optimi's asset-light strategy of supplying clinical trials rather than sponsoring them may reduce development risk while positioning the company to benefit from broader regulatory adoption of psychedelic-assisted therapies.
Optimi Health Corp. is a Canadian GMP-certified pharmaceutical manufacturer specializing in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies. The company's GMP certification is a key differentiator, as it ensures that its products meet stringent quality standards required for clinical trials and eventual prescription use.
The report's release comes at a time when the psychedelics sector is gaining increased attention from investors and regulators. Australia, in particular, has emerged as a key market for psychedelic therapies, with the Therapeutic Goods Administration (TGA) allowing authorized psychiatrists to prescribe MDMA and psilocybin for certain mental health conditions starting July 2023. Optimi has been actively expanding its presence in Australia, positioning itself to supply the growing demand.
For more information about Optimi Health Corp., visit https://www.optimi.net/. The full press release can be viewed at https://ibn.fm/DjgJF.
